Elevance Health is in a strong recovery uptrend, with the stock price up 20.3% over the past year, significantly outperforming the S&P 500's 20.6% gain. The current price of $416.23 sits at 97.3% of its 52-week range ($273.71–$427.64), indicating the stock is near its highs and reflecting robust momentum. This positioning near the top of the range suggests bullish sentiment but also implies limited upside in the near term without a catalyst to break through resistance. Short-term momentum is accelerating, with the stock gaining 2.9% over the past month and 33.6% over the past three months, far outpacing the S&P 500's 4.1% and 11.1% returns over the same periods. The 1-month relative strength of -1.2% versus the S&P 500 suggests a slight underperformance recently, but the 3-month relative strength of +22.5% confirms a strong intermediate-term trend. The divergence between the 1-month and 3-month trends may indicate a temporary consolidation phase within a broader uptrend. Key support lies at the 52-week low of $273.71, while resistance is at the 52-week high of $427.64. A breakout above $427.64 would signal a continuation of the uptrend and could open the door to further gains, while a breakdown below recent support near $380 (the April low) would suggest a trend reversal. With a beta of 0.68, Elevance is 32% less volatile than the S&P 500, making it a relatively defensive holding within the healthcare sector, which is attractive for risk-averse investors.

Elevance Health's revenue trajectory remains solidly growing, with Q4 2025 revenue of $49.7 billion representing a 9.5% year-over-year increase from Q4 2024's $45.4 billion. Over the trailing twelve months, revenue totaled $199.1 billion, up from $176.8 billion in the prior comparable period, driven by membership growth in health benefits and expansion of the Carelon Services segment, which contributed $18.7 billion in Q4 2025. However, growth has decelerated from the 14%+ pace seen in early 2024, reflecting a normalization after pandemic-related enrollment surges. The investment case hinges on sustained membership gains and cross-selling of higher-margin services. Profitability is solid but showed compression in Q4 2025, with net income of $547 million and a net margin of 1.1%, down from 5.3% in Q2 2025 due to higher operating costs and investment losses. Gross margin was 23.5% in Q4 2025, slightly below the 26.3% in Q2 2025, reflecting medical cost pressures. The operating margin of 1.2% in Q4 2025 was well below the 6.4% in Q1 2025, indicating seasonal or one-time headwinds. Despite the quarterly volatility, the company remains profitable with a trailing twelve-month net income of $5.6 billion, and margins are expected to recover as the company benefits from scale and cost management initiatives. Elevance maintains a healthy balance sheet with a debt-to-equity ratio of 0.76 and a current ratio of 1.24, indicating adequate liquidity. Free cash flow over the trailing twelve months was $3.2 billion, providing ample capacity for dividends, share repurchases, and strategic investments. The company generated $4.3 billion in operating cash flow over the past four quarters, with capital expenditures of $1.1 billion, resulting in a free cash flow yield of approximately 4.1% based on the current market cap. Return on equity stands at 12.9%, reflecting efficient capital utilization, while the payout ratio of 27% suggests room for dividend growth.